Related Experiment Video
Updated: Jul 29, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells
Kyung-Jun Lee1, Nam-Hyeok Kim1, Hyeong Su Kim1,2
1Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea.
Abstract:
Background and Objectives: Receptor tyrosine kinase-like orphan receptor type 1 (ROR1) plays a critical role in embryogenesis and is overexpressed in many malignant cells. These characteristics allow ROR1 to be a potential new target for cancer treatment. The aim of this study was to investigate the role of ROR1 through in vitro experiments in endometrial cancer cell lines. Materials and Methods: ROR1 expression was identified in endometrial cancer cell lines using Western blot and RT-qPCR. The effects of ROR1 on cell proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) markers were analyzed in two endometrial cancer cell lines (HEC-1 and SNU-539) using either ROR1 silencing or overexpression. Additionally, chemoresistance was examined by identifying MDR1 expression and IC50 level of paclitaxel. Results: The ROR1 protein and mRNA were highly expressed in SNU-539 and HEC-1 cells. High ROR1 expression resulted in a significant increase in cell proliferation, migration, and invasion. It also resulted in a change of EMT markers expression, a decrease in E-cadherin expression, and an increase in Snail expression. Moreover, cells with ROR1 overexpression had a higher IC50 of paclitaxel and significantly increased MDR1 expression. Conclusions: These in vitro experiments showed that ROR1 is responsible for EMT and chemoresistance in endometrial cancer cell lines. Targeting ROR1 can inhibit cancer metastasis and may be a potential treatment method for patients with endometrial cancer who exhibit chemoresistance.
Insights
Receptor tyrosine kinase-like orphan receptor type 1 (ROR1) drives endometrial cancer progression, metastasis, and chemoresistance. Targeting ROR1 may offer a new therapeutic strategy for endometrial cancer patients, particularly those resistant to chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Receptor tyrosine kinase-like orphan receptor type 1 (ROR1) is crucial in embryogenesis and frequently overexpressed in malignancies.
- ROR1 presents a promising therapeutic target for novel cancer treatments.
Purpose of the Study:
- To investigate the role of ROR1 in endometrial cancer cell lines through in vitro experiments.
- To analyze ROR1's impact on proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), and chemoresistance.
Main Methods:
- ROR1 expression was quantified using Western blot and RT-qPCR in HEC-1 and SNU-539 endometrial cancer cell lines.
- ROR1 silencing and overexpression were employed to assess effects on cellular behavior and EMT markers (E-cadherin, Snail).
- Chemoresistance was evaluated by measuring MDR1 expression and paclitaxel IC50 levels.
Main Results:
- High ROR1 expression correlated with increased proliferation, migration, and invasion in endometrial cancer cells.
- ROR1 influenced EMT markers, decreasing E-cadherin and increasing Snail expression.
- ROR1 overexpression led to increased paclitaxel IC50 and elevated MDR1 expression, indicating chemoresistance.
Conclusions:
- ROR1 plays a significant role in promoting EMT and chemoresistance in endometrial cancer.
- Targeting ROR1 could inhibit metastasis and represents a potential therapeutic approach for chemoresistant endometrial cancers.
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

